Barbeira, Alvaro N.
Bonazzola, Rodrigo
Gamazon, Eric R.
Liang, Yanyu
Park, YoSon
Kim-Hellmuth, Sarah
Wang, Gao
Jiang, Zhuoxun
Zhou, Dan
Hormozdiari, Farhad
Liu, Boxiang
Rao, Abhiram
Hamel, Andrew R.
Pividori, Milton D.
Aguet, François
Bastarache, Lisa
Jordan, Daniel M.
Verbanck, Marie
Do, Ron
Stephens, Matthew
Ardlie, Kristin
McCarthy, Mark
Montgomery, Stephen B.
Segrè, Ayellet V.
Brown, Christopher D.
Lappalainen, Tuuli
Wen, Xiaoquan
Im, Hae Kyung http://orcid.org/0000-0003-0333-5685
,
,
Funding for this research was provided by:
National Institute of Diabetes and Digestive and Kidney Diseases (P30DK20595)
National Institute of Health (R01MH107666)
Article History
Received: 6 June 2020
Accepted: 18 December 2020
First Online: 26 January 2021
Ethics approval and consent to participate
: Not applicable.
: F.A. is an inventor on a patent application related to TensorQTL; S.E.C. is a co-founder, chief technology officer, and stock owner at Variant Bio; E.R.G. is on the Editorial Board of Circulation Research, and does consulting for the City of Hope/Beckman Research Institute; E.T.D. is chairman and member of the board of Hybridstat LTD.; B.E.E. is on the scientific advisory boards of Celsius Therapeutics and Freenome; G.G. receives research funds from IBM and Pharmacyclics, and is an inventor on patent applications related to MuTect, ABSOLUTE, MutSig, MSMuTect, MSMutSig, POLYSOLVER, and TensorQTL. G.G. is a founder, consultant and holds privately held equity in Scorpion Therapeutics; S.B.M. is on the scientific advisory board of MyOme; D.G.M. is a co-founder with equity in Goldfinch Bio, and has received research support from AbbVie, Astellas, Biogen, BioMarin, Eisai, Merck, Pfizer, and Sanofi-Genzyme; H.K.I. has received speaker honoraria from GSK and AbbVie; T.L. is a scientific advisory board member of Variant Bio with equity and Goldfinch Bio. P.F. is a member of the scientific advisory boards of Fabric Genomics, Inc., and Eagle Genomes, Ltd. P.G.F. is a partner of Bioinf2Bio.